Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
LSL Pharma Group Inc ( (TSE:LSL) ) has shared an update.
LSL Pharma Group has granted a total of 960,000 stock options to its non-executive directors, executives and employees as part of their compensation, with an exercise price of C$0.52 per share and a ten-year term. Options for non-executive directors vest immediately, while those for executives and employees vest over three years, and all options and any resulting shares are subject to a four-month hold period under TSX Venture Exchange rules, underscoring the company’s use of equity incentives to align management and staff with long-term shareholder value creation.
More about LSL Pharma Group Inc
LSL Pharma Group Inc. is a Canadian integrated pharmaceutical company focused on the development, manufacturing and commercialization of high-quality sterile ophthalmic drugs, as well as pharmaceutical, cosmetic and natural health products in solid, semi-solid and liquid dosage forms. The company operates through several wholly owned subsidiaries, including Steri-Med Pharma, LSL Laboratory, Virage Santé, Dermolab Pharma, Du-Var Laboratory and Juno OTC, leveraging certified facilities and technical expertise to serve specialized healthcare and consumer markets.
Average Trading Volume: 81,238
Technical Sentiment Signal: Buy
Current Market Cap: C$64.25M
For a thorough assessment of LSL stock, go to TipRanks’ Stock Analysis page.